{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:04:51Z","timestamp":1789391091905,"version":"build-2803163510"},"reference-count":46,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Personalized mRNA neoantigen vaccines represent an emerging form of precision cancer immunotherapy designed to generate de novo T-cell responses against patient-specific tumor mutations. Their therapeutic activity, however, depends not only on neoantigen selection and vaccine-induced immune priming but also on whether these responses can remain functional within an immunosuppressive tumor microenvironment. Immune checkpoint blockade provides a mechanistically complementary strategy by relieving inhibitory signaling that constrains vaccine-expanded tumor-reactive lymphocytes. This review examines this therapeutic interface across three interconnected levels: molecular neoantigen selection and mRNA vaccine design, vaccine-driven remodeling of antitumor T-cell immunity, and clinical integration with PD-1\/PD-L1 blockade. Particular emphasis is placed on how neoantigen clonality, antigen presentation, tumor heterogeneity, and immune escape influence the translation of vaccine immunogenicity into clinical benefit. Current evidence is evaluated across melanoma, non-small cell lung cancer, and pancreatic ductal adenocarcinoma, including randomized and ongoing trials of intismeran autogene, an individualized synthetic mRNA therapy encoding patient-specific neoantigens, and autogene cevumeran, an individualized uridine mRNA-lipoplex neoantigen vaccine. By integrating molecular vaccine design with tumor evolution, immune-contexture remodeling, and checkpoint sensitivity, this review identifies determinants that may distinguish successful immune priming from durable therapeutic efficacy and outlines priorities for biomarker-guided patient selection and future combination strategies.<\/jats:p>","DOI":"10.3390\/ijms27188163","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:09:51Z","timestamp":1789387791000},"page":"8163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-9893","authenticated-orcid":false,"given":"Turan","family":"Demircan","sequence":"first","affiliation":[{"name":"Medical Biology Department, School of Medicine, \u0130zmir Bak\u0131r\u00e7ay University, \u0130zmir 35665, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-2586","authenticated-orcid":false,"given":"Berna","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil \u0130brahim","family":"\u00dcnsal","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Provincial Directorate of Health, Diyarbakir 21120, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9399-5927","authenticated-orcid":false,"given":"Ayhan","family":"Bilir","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., and Zhao, X. (2022). Mechanisms of Tumor Resistance to Immune Checkpoint Blockade and Combination Strategies to Overcome Resistance. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.915094"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune Checkpoint Therapy for Solid Tumours: Clinical Dilemmas and Future Trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of Neoantigens for Individualised Cancer Immunotherapy","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s43018-022-00352-7","article-title":"Concurrent Delivery of Immune Checkpoint Blockade Modulates T Cell Dynamics to Enhance Neoantigen Vaccine-Generated Antitumor Immunity","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e010569","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA Technology for Antigen Based Immuno-Oncology Therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory Mechanisms of PD-1\/PD-L1 in Cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised Neoantigen Therapy mRNA-4157 (V940) plus Pembrolizumab versus Pembrolizumab Monotherapy in Resected Melanoma (KEYNOTE-942): A Randomised, Phase 2b Study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO-26-00835","article-title":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","volume":"44","author":"Khattak","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_9","unstructured":"Merck Sharp & Dohme LLC (2026, September 03). A Phase 3 Randomized Double-Blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants with Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab with Platinum-Based Doublet Chemotherapy (INTerpath-009). Available online: https:\/\/www.istitutotumori.mi.it\/en\/clinical-trials\/phase-3-randomized-double-blind-study-adjuvant-pembrolizumab-or-without-v940-participants-resectable-stage-ii-iiib-n2-nsclc-not-achieving-pcr-after."},{"key":"ref_10","unstructured":"Merck Sharp & Dohme LLC (2026, September 03). A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-Small Cell Lung Cancer (INTerpath-002). Available online: https:\/\/cancer.osu.edu\/for-patients-and-caregivers\/learn-about-cancers-and-treatments\/innovation-at-the-james\/clinical-trials\/find-a-clinical-trial\/a-phase-iii-randomized-doubleblind-placebo."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA Neoantigen Vaccines Prime Long-Lived CD8+ T Cells in Pancreatic Cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A Comprehensive Proteogenomic Pipeline for Neoantigen Discovery to Advance Personalized Cancer Immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13073-024-01384-7","article-title":"pVACview: An Interactive Visualization Tool for Efficient Neoantigen Prioritization and Selection","volume":"16","author":"Xia","year":"2024","journal-title":"Genome Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Imani, S., Li, X., Chen, K., Maghsoudloo, M., Jabbarzadeh Kaboli, P., Hashemi, M., Khoushab, S., and Li, X. (2025). Computational Biology and Artificial Intelligence in mRNA Vaccine Design for Cancer Immunotherapy. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1501010"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The Role of Neoantigens and Tumor Mutational Burden in Cancer Immunotherapy: Advances, Mechanisms, and Perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A Shared Neoantigen Vaccine Combined with Immune Checkpoint Blockade for Advanced Metastatic Solid Tumors: Phase 1 Trial Interim Results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene Cevumeran with or without Atezolizumab in Advanced Solid Tumors: A Phase 1 Trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"218459","DOI":"10.1016\/j.canlet.2026.218459","article-title":"A circRNA Neoantigen Vaccine Elicits Potent Antitumor Immunity and Synergizes with Checkpoint Blockade in Melanoma","volume":"648","author":"Wu","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in Developing Personalized Neoantigen Cancer Vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e003821","DOI":"10.1136\/jitc-2021-003821","article-title":"Targeting the Tumor Mutanome for Personalized Vaccination in a TMB Low Non-Small Cell Lung Cancer","volume":"10","author":"McCann","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zanotta, S., Galati, D., De Filippi, R., and Pinto, A. (2024). Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202406.0880.v1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen Presentation in Cancer: Insights into Tumour Immunogenicity and Immune Evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e010249","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen Architectures Define Immunogenicity and Drive Immune Evasion of Tumors with Heterogenous Neoantigen Expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105543","DOI":"10.1016\/j.ebiom.2024.105543","article-title":"Nanostructured Lipid Carriers Based mRNA Vaccine Leads to a T Cell-Inflamed Tumour Microenvironment Favourable for Improving PD-1\/PD-L1 Blocking Therapy and Long-Term Immunity in a Cold Tumour Model","volume":"112","author":"Fournier","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Persico, I., Doro, M.G., Frogheri, L., Sini, M.C., Maestrale, G.B., Manca, A., Mallardo, D., Ascierto, P.A., and Palmieri, G. (2026). How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma. Cells, 15.","DOI":"10.3390\/cells15110986"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yu, X., and Fu, K. (2026). Neoantigen-Based Cancer Vaccines: A Mechanistic and Clinical Review of Personalised Melanoma Immunotherapy. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1808146"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zoroddu, S., and Bagella, L. (2025). Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. Cells, 14.","DOI":"10.3390\/cells14181476"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2500008","DOI":"10.1200\/OA-25-00008","article-title":"Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma","volume":"3","author":"Carlino","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"ref_31","unstructured":"Merck Sharp & Dohme LLC (2026, September 03). A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with First-Line Advanced Melanoma (INTerpath-012). Available online: https:\/\/www.istitutotumori.mi.it\/en\/clinical-trials\/studio-clinico-fase-2-randomizzato-doppio-cieco-v940-mrna-4157-piu-pembrolizumab-rispetto-placebo-piu-pembrolizumab-prima-linea-partecipanti-melanoma."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"TPS9616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616","article-title":"INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus Pembrolizumab with Placebo for Adjuvant Treatment of High-Risk Stage II-IV Melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","unstructured":"Merck & Co., Inc., and Moderna, Inc. (2026, September 03). Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA\u00ae Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients with Completely Resected Stage IIB\u2013IV Melanoma. Available online: https:\/\/www.merck.com\/news\/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-026-01778-7","article-title":"Lung Cancer Vaccines to Enhance Immune Checkpoint Inhibitor Therapy: Evidence and Future Perspectives","volume":"19","author":"Tang","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","first-page":"21","article-title":"Tumor Microenvironment-Driven Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Strategies for Cold-to-Hot Tumor Transformation","volume":"8","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_36","unstructured":"Merck Sharp & Dohme LLC (2026, September 03). A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Participants with Metastatic Squamous NSCLC (INTerpath-013). Available online: https:\/\/www.istitutotumori.mi.it\/en\/clinical-trials\/phase-2-randomized-double-blind-placebo-controlled-study-v940-combination-pembrolizumab-and-chemotherapy-first-line-treatment-participants-metastatic."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal Driver Neoantigen Loss under EGFR TKI and Immune Selection Pressures","volume":"639","author":"Reading","year":"2025","journal-title":"Nature"},{"key":"ref_39","unstructured":"Genentech, Inc. (2026, September 03). A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma. Available online: https:\/\/www.cancer.columbia.edu\/cancer-types-care\/clinical-trials\/find-clinical-trial\/phase-ii-open-label-multicenter-randomized-study-efficacy-and-safety-adjuvant-autogene-cevumeran-plus-atezolizumab-and-mfolfirinox-versus-mfolfirinox-alone-patients-resected-pancreatic-ductal."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of Unique Neoantigen Qualities in Long-Term Survivors of Pancreatic Cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Masugi, Y. (2022). The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Cancers, 14.","DOI":"10.3390\/cancers14133293"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, Heterologous Chimpanzee Adenovirus and Self-Amplifying mRNA Neoantigen Vaccine for Advanced Metastatic Solid Tumors: Phase 1 Trial Interim Results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_43","unstructured":"Genentech, Inc. (2026, September 03). A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma. Available online: https:\/\/www.dana-farber.org\/clinical-trials\/19-022."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A Neoantigen Vaccine Generates Antitumour Immunity in Renal Cell Carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination Strategies with PD-1\/PD-L1 Blockade: Current Advances and Future Directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2458936","DOI":"10.1080\/21645515.2025.2458936","article-title":"Neoantigen mRNA Vaccines and A2A Receptor Antagonism: A Strategy to Enhance T Cell Immunity","volume":"21","author":"Imani","year":"2025","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:27:54Z","timestamp":1789388874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":46,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188163"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188163","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}